Merrimack Pharmaceuticals, Inc.
Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics

Abstract:

EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of EphA2 positive cancer comprising cancer cells expressing over about 3000 EphA2 receptors/cell. Diagnostic methods for identifying EphA2 positive cancer patients and methods of treating identified patients with a Eph-A2 targeted nanoliposome encapsulating a docetaxel prodrug are provided.